BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chow PK, Gandhi M, Gebski V. The SIRveNIB and SARAH trials and the role of SIR-Spheres® Y-90 resin microspheres in the management of hepatocellular carcinoma. Future Oncology 2017;13:2213-6. [DOI: 10.2217/fon-2017-0395] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Swersky A, Kulik L, Kalyan A, Grace K, Caicedo JC, Lewandowski RJ, Salem R. Contemporary Algorithm for the Management of Hepatocellular Carcinoma in 2021: The Northwestern Approach. Semin Intervent Radiol 2021;38:432-7. [PMID: 34629710 DOI: 10.1055/s-0041-1735528] [Reference Citation Analysis]
2 Spallanzani A, Orsi G, Andrikou K, Gelsomino F, Rimini M, Riggi L, Cascinu S. Lenvatinib as a therapy for unresectable hepatocellular carcinoma. Expert Rev Anticancer Ther. 2018;18:1069-1076. [PMID: 30220234 DOI: 10.1080/14737140.2018.1524297] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
3 Llovet JM, Finn RS. Negative phase 3 study of 90 Y microspheres versus sorafenib in HCC. The Lancet Oncology 2018;19:e69. [DOI: 10.1016/s1470-2045(18)30025-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]